Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Dose Titration Study of ANAVEX2-73 in Patients With Rett Syndrome

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Blarcamesine (Primary)
Indications Rett syndrome
Focus Adverse reactions; Biomarker; Pharmacokinetics; Therapeutic Use
Acronyms U.S. RTT
Sponsors Anavex Life Sciences

Most Recent Events

28 Jun 2023 According to an Anavex Life Sciences media release, Anavex plans to submit the data for publication in a peer-reviewed medical journal.
28 Jun 2023 Results published in the Anavex Life Sciences Media Release
21 Jun 2021 Results published in an Anavex Life Sciences Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com